Brief: Vaccitech Renames as Barinthus Biotherapeutics
06/11/2023 14:27
Nov 6 (Reuters) - Vaccitech PLC VACC.O :
* VACCITECH RENAMES AS BARINTHUS BIOTHERAPEUTICS TO
HIGHLIGHT
STRATEGIC EVOLUTION INTO A T CELL IMMUNOTHERAPY COMPANY
TARGETING CHRONIC INFECTIOUS DISEASES, AUTOIMMUNITY, AND CANCER
* VACCITECH PLC- COMPANY EXPECTS TO BEGIN TRADING UNDER ITS
NEW
NAME AND TICKER (NASDAQ: BRNS) EFFECTIVE AS OF NOVEMBER 7
Source text for Eikon: ID:nGNX9BGxRW
Further company coverage: VACC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Barinthus Biotherapeutics
See all newsBrief: Barinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics
Brief: Barinthus Biotherapeutics PLC Appoints Douglas Swirsky As CFO And Principal Accounting Officer Effective May 1, 2026
Brief: Barinthus Bio Announces Update On Phase 1 AVALON Clinical Trial Of VTP-1000 For The Treatment Of Celiac Disease
Brief: Barinthus Bio Reports Second Quarter 2025 Financial Results And Updates On Corporate Developments
Gemma Brown Terminated As CFO Effective April 30, 2025 - SEC Filing